Rheumatoid arthritis

Identifying Resolution of Clinically Suspect Arthralgia: A Step Toward Understanding Spontaneous Reversal of an At-Risk Stage of Rheumatoid Arthritis

J RheumatolPublished Prospective cohort study

Authors' conclusion

Clinically, reversal of at-risk stage is better defined by rheumatologist-confirmed resolution of CSA, rather than a single patient-reported measure such as pain. CSA resolution was associated with improved subclinical joint inflammation and functional disabilities.

Study context

Population
Patients with clinically suspect arthralgia (CSA), at-risk stage of rheumatoid arthritis (RA)505 eligible for reversal
Participants
845 patients
Exposure
Patient-reported pain resolution vs rheumatologist-defined CSA resolution as definitions of reversal
Outcome
Reversal: patient-reported pain resolution (pain score ≤ 20 on NRS 0-100) and rheumatologist-defined resolution of CSA
Follow-up
2 years
Methodological detailsconsecutively included patients, 2-year follow-up
  • Consecutively included patients
  • 2-year follow-up

Main finding

As reported in the abstract

Reversal among patients eligible for reversal

Pain resolution

244/505 patients

48%

Rheumatologist-defined CSA resolution

357 of 505

71%

Observational data: associations, not effects.

Further findings

Outcomeβ (/year) (95% CI)P value
Change over time in functional disabilities, in patients with CSA resolution (β per year; negative = less disability, improved)Functional disabilities improved over time−0.07 (−0.09 to −0.05)P < 0.001

Baseline characteristics, CSA resolution vs no CSA resolution · presentation

Similar levels of subclinical joint inflammation at presentation
Less pain, fatigue and morning stiffness with CSA resolution than without

Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.

Original publication

Identifying Resolution of Clinically Suspect Arthralgia: A Step Toward Understanding Spontaneous Reversal of an At-Risk Stage of Rheumatoid Arthritis. J Rheumatol. Published 1 September 2025. doi:10.3899/jrheum.2025-0052

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.